Live Breaking News & Updates on Cortrophin Gel|Page 3

Stay updated with breaking news from Cortrophin gel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ANI Pharmaceuticals Stock: Strong Revenue Growth, ANDA Approvals (ANIP)

ANI Pharmaceuticals exceeded Q1 Non-GAAP earnings expectations and raised its guidance to $385-$410 million. See why I rate ANIP stock a Strong Buy here. ....

New Jersey , United States , Alpha Dulan Lokuwithana , Alpha Quant , Company Financials , Other Pharmaceutical Services , Pharmaceuticals Inc , Ani Pharmaceuticals Inc , Generic Pharmaceutical Products , Established Brand Pharmaceutical Products , Rare Disease Pharmaceutical , Competitive Generic Therapy , Abbreviated New Drug Applications , Nitrofurantoin Oral Suspension , Colestipol Hydrochloride Tablets , Seeking Alpha , Dulan Lokuwithana , Cortrophin Gel , Long Term Debt , Strong Buy ,

ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

First Quarter 2023 Financial Results

Record quarterly net revenues of $106.8 million, representing year-over-year growth of 65.6%; 2023 first-quarter net income available to common shareholders. | May 8, 2023 ....

New Jersey , United States , Nikhil Lalwani , Novitium Pharma , Research Development Or Cortrophin Gel , Exchange Commission , Drug Administration , Pharmaceuticals Inc , Rare Disease , Purified Cortrophin , Cortrophin Gel , Established Brands , Recent Business Highlights , Competitive Generic Therapy , Abbreviated New Drug Applications , Nitrofurantoin Oral Suspension , Colestipol Hydrochloride Tablets , Good Manufacturing Practices , Months Ended March , In Process Research , North American , Private Securities Litigation Reform Act , Before Income Tax , Convertible Preferred , Diluted Income , Per Share ,

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and R

Second Quarter 2022 Results: Net revenues of $73.9 million, net loss available to common shareholders of $(15.3) million and diluted GAAP loss per share of $(0.94) – Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin) net sales of $10.2 million Ad. ....

United States , Nikhil Lalwani , Lisam Wilson , Meredithw Cook , Oakrum Pharma , Exchange Commission , Oakrum Pharmaceuticals , Drug Administration , Site Communications Inc , Pharmaceuticals Inc , Business Development , Second Quarter , Rare Disease , Repository Corticotrophin Injection , Per Share , General Counsel , Purified Cortrophin Gel , United Healthcare , Launch Update , Growth Engine Update , Cortrophin Gel , Net Revenue , North American , Private Securities Litigation Reform Act , Annual Report , Months Ended June ,

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin Gel

08.08.2022 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and six months ended June 30, 2022. “Second quarter net revenues of $73.9 million represent a new quarterly record . ....

United States , Oakrum Pharma , Exchange Commission , Drug Administration , Pharmaceuticals Inc , Business Development , Launch Update , United Healthcare , Growth Engine Update , Cortrophin Gel , Net Revenue , Purified Cortrophin Gel , North American , Private Securities Litigation Reform , Annual Report , Months Ended June , Before Benefit , Income Taxes , Convertible Preferred Stock , Loss Available , Common Shareholders , Diluted Loss Per Share , Mezzanine Equity , Stockholder Equity , Income Available , Ani Pharmaceuticals ,

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

/PRNewswire/ ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) and Veeva Systems (NYSE: VEEV) today announced a collaboration to define and operationalize. ....

United States , Christopher Mutz , Angela Salerno Robin , Paul Shawah , Deivis Mercado , Pharmaceuticals Media Contact , Exchanges Commission , A Public Benefit Corporation , Pharmaceuticals Inc , Veeva Systems , Rare Disease Business , Purified Cortrophin , Repository Corticotropin Injection , Veeva Commercial Cloud , Business Consulting , Public Benefit Corporation , North American , Private Securities Litigation Reform Act , Cortrophin Gel ,